# Cardio-Metabolic Sector

Canonical URL: https://biopharmsignal.com/sector/cardio-metabolic

Cardio-Metabolic includes companies targeting cardiovascular disease, obesity, diabetes, lipid disorders, and related metabolic conditions. This page highlights businesses exposed to some of the largest and most competitive treatment categories in biotech and pharma.

Companies currently grouped under Cardio-Metabolic: 27

## Recent Sector News

- 2026-07-20 10:59 EST — BMY — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-16 12:31 EST — MRK — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-15 12:31 EST — MRK — [KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy](https://biopharmsignal.com/news/MRK/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-ceac984b) — Source: Merck
- 2026-07-15 12:31 EST — MRK — [Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026](https://biopharmsignal.com/news/MRK/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-f70a5c44) — Source: Merck
- 2026-07-14 11:00 EST — BEAT — [HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device](https://biopharmsignal.com/news/BEAT/heartbeam-awarded-new-u-s-patent-expanding-acoustic-sensing-and-fluid-monitoring-e0c78764) — Source: HeartBeam
- 2026-07-13 10:59 EST — BMY — [U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma](https://biopharmsignal.com/news/BMY/u-s-food-and-drug-administration-accepts-bristol-myers-squibb-s-new-drug-applica-b21b9788) — Source: BMYBristol-Myers Squibb Company
- 2026-07-10 19:01 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-7cdef535) — Source: Merck
- 2026-07-10 10:06 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC) - Merck.com](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-bc1625e5) — Source: Merck
- 2026-07-10 10:06 EST — MRK — [Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV - Merck.com](https://biopharmsignal.com/news/MRK/merck-announces-new-agreement-with-adap-crisis-task-force-to-improve-access-and--4390af46) — Source: Merck
- 2026-07-10 10:06 EST — MRK — [Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4 - Merck.com](https://biopharmsignal.com/news/MRK/merck-to-hold-second-quarter-2026-sales-and-earnings-conference-call-aug-4-merck-44a90bf3) — Source: Merck
- 2026-07-09 19:07 EST — MRK — [Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment - Merck.com](https://biopharmsignal.com/news/MRK/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-eval-bb1d1ada) — Source: Merck
- 2026-07-09 11:56 EST — MRK — [FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC) - Merck.com](https://biopharmsignal.com/news/MRK/fda-approves-keytruda-pembrolizumab-and-keytruda-qlex-pembrolizumab-and-berahyal-e15b5e64) — Source: Merck
- 2026-07-09 11:56 EST — MRK — [U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease - Merck.com](https://biopharmsignal.com/news/MRK/u-s-fda-approves-an-additional-indication-for-capvaxive-pneumococcal-21-valent-c-0b81d0d3) — Source: Merck
- 2026-07-09 11:56 EST — MRK — [Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Merck.com](https://biopharmsignal.com/news/MRK/merck-s-tulisokibart-met-primary-and-key-secondary-endpoints-in-the-phase-3-atla-f40c0831) — Source: Merck
- 2026-07-09 11:56 EST — MRK — [European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer - Merck.com](https://biopharmsignal.com/news/MRK/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedot-b45629ae) — Source: Merck
- 2026-07-08 15:00 EST — AGIO — [Quality Beyond Compliance: Malik Khan, Hologic VP of Quality](https://biopharmsignal.com/news/AGIO/quality-beyond-compliance-malik-khan-hologic-vp-of-quality-280d52d0) — Source: Agios Pharmaceuticals, Inc.
- 2026-07-08 15:00 EST — AGIO — [Mireille Akilian on Women’s Health & GYN Surgical Innovation | Hologic](https://biopharmsignal.com/news/AGIO/mireille-akilian-on-women-s-health-gyn-surgical-innovation-hologic-f5dedd97) — Source: Agios Pharmaceuticals, Inc.
- 2026-07-08 15:00 EST — AGIO — [Fibroid Care Innovation: Listening, Learning, Engineering | Hologic](https://biopharmsignal.com/news/AGIO/fibroid-care-innovation-listening-learning-engineering-hologic-1f5b2dec) — Source: Agios Pharmaceuticals, Inc.
- 2026-07-08 15:00 EST — AGIO — [Tom Kelly, Co-Inventor of the T-Score, on the Science of DXA and Its Role in Protecting Women’s Bone Health Across Life Stages](https://biopharmsignal.com/news/AGIO/tom-kelly-co-inventor-of-the-t-score-on-the-science-of-dxa-and-its-role-in-prote-6c7ab5bb) — Source: Agios Pharmaceuticals, Inc.
- 2026-07-03 01:30 EST — MIST — [Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MIST/milestone-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-56-74d5744c) — Source: Milestone Pharmaceuticals Inc.

## Companies

- [AGIO](https://biopharmsignal.com/company/AGIO) — Agios Pharmaceuticals, Inc.
- [AMGN](https://biopharmsignal.com/company/AMGN) — Amgen Inc.
- [AZN](https://biopharmsignal.com/company/AZN) — AstraZeneca PLC
- [BMY](https://biopharmsignal.com/company/BMY) — BMYBristol-Myers Squibb Company
- [CMXC](https://biopharmsignal.com/company/CMXC) — Cell MedX
- [CORT](https://biopharmsignal.com/company/CORT) — Corcept
- [EW](https://biopharmsignal.com/company/EW) — Edwards Lifesciences
- [LLY](https://biopharmsignal.com/company/LLY) — Eli Lilly
- [EMBC](https://biopharmsignal.com/company/EMBC) — Embecta
- [GLS](https://biopharmsignal.com/company/GLS) — Gelesis
- [BEAT](https://biopharmsignal.com/company/BEAT) — HeartBeam
- [HSCS](https://biopharmsignal.com/company/HSCS) — HeartSciences
- [MNKD](https://biopharmsignal.com/company/MNKD) — MannKind
- [MRK](https://biopharmsignal.com/company/MRK) — Merck
- [MIST](https://biopharmsignal.com/company/MIST) — Milestone Pharmaceuticals Inc.
- [NURO](https://biopharmsignal.com/company/NURO) — Neurometrix
- [NAMS](https://biopharmsignal.com/company/NAMS) — NewAmsterdam Pharma
- [NVS](https://biopharmsignal.com/company/NVS) — Novartis AG
- [NVO](https://biopharmsignal.com/company/NVO) — Novo Nordisk
- [PFE](https://biopharmsignal.com/company/PFE) — Pfizer, Inc.
- [PMCB](https://biopharmsignal.com/company/PMCB) — PharmaCyte Biotech
- [RSLS](https://biopharmsignal.com/company/RSLS) — ReShape Lifesciences
- [RZLT](https://biopharmsignal.com/company/RZLT) — Rezolute
- [SWAV](https://biopharmsignal.com/company/SWAV) — Shockwave Medical
- [VERV](https://biopharmsignal.com/company/VERV) — Verve Therapeutics
- [VTRS](https://biopharmsignal.com/company/VTRS) — Viatris Inc.
- [VKTX](https://biopharmsignal.com/company/VKTX) — Viking Therapeutics